Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is quickly establishing itself as a major player, ...

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.